Ascendis Pharma (ASND) announced that it has granted Novo Nordisk (NVO) an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases and a product-by-product exclusive license in cardiovascular diseases. The agreement includes provisions requiring certain TransCon technology-based products to be identified and advanced in metabolic diseases to maintain exclusivity in the field and additional provisions for cardiovascular diseases. Under the terms of the agreement, Novo Nordisk also receives exclusive rights to expand any resulting metabolic disease products into other therapeutic areas. The lead program in the collaboration is a once-monthly GLP-1 receptor agonist product candidate that will initially target obesity and type 2 diabetes.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma A/S (ASND) Q3 Earnings Cheat Sheet
- BioMarin price target lowered to $90 from $110 at Cantor Fitzgerald
- Ascendis Pharma price target lowered to $174 from $180 at JPMorgan
- 3 Best Stocks to Buy Now, 10/21/2024, According to Top Analysts
- Ascendis Pharma price target raised to $160 from $157 at TD Cowen